adimab.com
Bispecifics | Adimab
http://www.adimab.com/bispecifics
Skip to main content. How to Work with Adimab. Publications by Adimab Scientists. Adimab can work with almost any format. Adimab discovers better molecules by optimizing in the final therapeutic format. Our key advantages are:. Ability to present full-length bispecifics on the surface of yeast. Dramatically improved success with expression in mammalian hosts. Creation of library diversities that are unprecedented for bispecific IgGs ( 10. Flexibility in choice of format:.
pharmstd.lu
Pharmstandard International S.A. - Société anonyme
http://www.pharmstd.lu/fr.html
A propos de l’entreprise. Pharmstandard International S.A. Pharmstandard International S.A. est une entreprise axée sur les investissements de capital-risque pour des médicaments innovants et à fort potentiel sur les marchés mondiaux et en Russie. La société a été fondée le 8 décembre 2010 et est une filiale appartenant à 100 % à PJSC Pharmstandard. LSE:PHST) le leader pharmaceutique russe. Vous trouverez ci-dessous de courtes descriptions de nos investissements. Newton, MA, États-Unis. Pour plus d’infor...
adimab.com
Existing Partners | Adimab
http://www.adimab.com/existing-partners
Skip to main content. How to Work with Adimab. Publications by Adimab Scientists. How to Work with Adimab. Committed to finding truly next-generation antibody technology. Adimab was spot on. We engaged in a rigorous selection process and Adimab was the clear winner. We are particularly impressed with the ability to optimize antibodies with this broad engineering tool. Adimab's technology does what no other technology can do. One of the best, if not the best, platform out there. Just a fantastic partner!
pharmstd.lu
Pharmstandard International S.A. - Societe anonyme
http://www.pharmstd.lu/de.html
Pharmstandard International S.A. Pharmstandard International S.A. ist ein Unternehmen mit Schwerpunkt auf Risikokapital-Investitionen in innovativer Medizin mit starkem Potenzial auf dem Weltmarkt und in Russland. Das Unternehmen wurde am 8. Dezember 2010 gegründet und ist ein hundertprozentiges Tochterunternehmen von PJSC Pharmstandard. LSE:PHST) - Russlands führendem. Kurze Beschreibungen der Investitionen finden Sie unten. Newton, MA, USA. NASDAQ:ARGS / Durham, NC, USA. Argos Therapeutics ist ein biop...
inbio-ventures.com
News - Inbio Ventures
http://www.inbio-ventures.com/news
Pharmstandard International S.A. Represented by Inbio Ventures Leads a $20M Syndicated Series C Financing in Avelas Biosciences. Moscow, August 18, 2016. In conjunction with the financing, Andrei Petrov, Ph.D, the chief executive officer and managing partner at Inbio Ventures, has joined Avelas Bioscience’s board of directors. At the same time, Kevin Kinsella and Nikolay Savchuk will be stepping down as directors of the company. I am delighted to have some of the world’s most prominent healthcare investo...
inbio-ventures.com
Pharmstandard International S.A. represented by Inbio Ventures participated in Series B Financing of Jounce Therapeutics with a solid group of investors - Inbio Ventures
http://www.inbio-ventures.com/news/pharmstandard-international-s-a-represented-by-inbio-ventures-participated-in-series-b-financing-of-jounce-therapeutics-with-a-solid-group-of-investors
Pharmstandard International S.A. represented by Inbio Ventures participated in Series B Financing of Jounce Therapeutics with a solid group of investors. MOSCOW, Russia. April 23, 2015. Jounce Therapeutics, Inc. Participation in the round included Wellington Management Company, Redmile Group, Nextech Invest, Pharmstandard International, Cormorant Asset Management, Omega Funds, Casdin Capital, Foresite Capital Management and an undisclosed blue chip public investment fund. Pure Communications, Inc.
